GI
MIRM icon

Gradient Investments’s Mirum Pharmaceuticals MIRM Stock Holding History

Gradient Investments’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18
Closed -$531 – 1594
2023
Q4 		$531 Hold
18
– – ﹤0.01% 1581
2023
Q3 		$569 Hold
18
– – ﹤0.01% 1523
2023
Q2 		$466 Hold
18
– – ﹤0.01% 1548
2023
Q1 		$432 Hold
18
– – ﹤0.01% 1297
2022
Q4 		$351 Buy
+18
New +$356 ﹤0.01% 1327

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gradient Investments's MIRM Position: Q1 2024 in Review

Gradient Investments sold out of Mirum Pharmaceuticals (MIRM) in Q1 2024, closing a stake of 18 shares — an estimated $531 sold.

Gradient Investments first reported a position in MIRM in Q4 2022 and held it in 5 quarters. The position peaked at $569 in Q3 2023. 172 funds tracked by Wall St. Rank hold MIRM as of Q1 2024.

  • Gradient Investments reported no remaining Mirum Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Gradient Investments sold 18 Mirum Pharmaceuticals shares in Q1 2024, an estimated $531.
  • Gradient Investments first reported a position in Mirum Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Gradient Investments's Mirum Pharmaceuticals position peaked at $569 in Q3 2023.
  • 172 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2024.

Based on Gradient Investments's 13F filing for Q1 2024, filed 23 Apr 2024.